<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:16:27Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8330577" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8330577</identifier>
        <datestamp>2021-08-20</datestamp>
        <setSpec>openheart</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Open Heart</journal-id>
              <journal-id journal-id-type="iso-abbrev">Open Heart</journal-id>
              <journal-id journal-id-type="hwp">openhrt</journal-id>
              <journal-id journal-id-type="publisher-id">openheart</journal-id>
              <journal-title-group>
                <journal-title>Open Heart</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2053-3624</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8330577</article-id>
              <article-id pub-id-type="pmcid">PMC8330577</article-id>
              <article-id pub-id-type="pmc-uid">8330577</article-id>
              <article-id pub-id-type="pmid">34341098</article-id>
              <article-id pub-id-type="publisher-id">openhrt-2021-001710</article-id>
              <article-id pub-id-type="doi">10.1136/openhrt-2021-001710</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Special Populations</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                </subj-group>
                <series-title>Original research</series-title>
              </article-categories>
              <title-group>
                <article-title>Protective lipid-lowering variants in healthy older individuals without coronary heart disease</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-87424756" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0902-6798</contrib-id>
                  <name>
                    <surname>Lacaze</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87424773" contrib-type="author">
                  <name>
                    <surname>Riaz</surname>
                    <given-names>Moeen</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87424775" contrib-type="author">
                  <name>
                    <surname>Sebra</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-35922344" contrib-type="author">
                  <name>
                    <surname>Hooper</surname>
                    <given-names>Amanda J</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-35927427" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9700-6948</contrib-id>
                  <name>
                    <surname>Pang</surname>
                    <given-names>Jing</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-87424778" contrib-type="author">
                  <name>
                    <surname>Tiller</surname>
                    <given-names>Jane</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87424779" contrib-type="author">
                  <name>
                    <surname>Polekhina</surname>
                    <given-names>Galina</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-34773453" contrib-type="author">
                  <name>
                    <surname>Tonkin</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-34773846" contrib-type="author">
                  <name>
                    <surname>Reid</surname>
                    <given-names>Chris</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-53462784" contrib-type="author">
                  <name>
                    <surname>Zoungas</surname>
                    <given-names>Sophia</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87424783" contrib-type="author">
                  <name>
                    <surname>Murray</surname>
                    <given-names>Anne M</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-77571422" contrib-type="author">
                  <name>
                    <surname>Nicholls</surname>
                    <given-names>Stephen</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-34774464" contrib-type="author">
                  <name>
                    <surname>Watts</surname>
                    <given-names>Gerald</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-87424786" contrib-type="author">
                  <name>
                    <surname>Schadt</surname>
                    <given-names>Eric</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-25730619" contrib-type="author">
                  <name>
                    <surname>McNeil</surname>
                    <given-names>John J</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine</institution>, <institution>Monash University</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Genetics and Genomic Sciences</institution>, <institution>Icahn School of Medicine at Mount Sinai</institution>, <addr-line content-type="city">New York</addr-line>, <addr-line content-type="state">New York</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">School of Medicine, Faculty of Medicine and Health Sciences</institution>, <institution>The University of Western Australia</institution>, <addr-line content-type="city">Perth</addr-line>, <addr-line content-type="state">Western Australia</addr-line>, <country>Australia</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network</institution>, <institution>Royal Perth Hospital</institution>, <addr-line content-type="city">Perth</addr-line>, <addr-line content-type="state">Western Australia</addr-line>, <country>Australia</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">School of Public Health</institution>, <institution>Curtin University</institution>, <addr-line content-type="city">Perth</addr-line>, <addr-line content-type="state">Western Australia</addr-line>, <country>Australia</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute</institution>, <institution>Hennepin Healthcare</institution>, <addr-line content-type="city">Minneapolis</addr-line>, <addr-line content-type="state">Minnesota</addr-line>, <country>USA</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Monash Cardiovascular Research Centre, Monash University and MonashHeart</institution>, <institution>Monash Health</institution>, <addr-line content-type="city">Clayton</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Lipid Disorders Clinic, Department of Cardiology</institution>, <institution>Royal Perth Hospital</institution>, <addr-line content-type="city">Perth</addr-line>, <addr-line content-type="state">Western Australia</addr-line>, <country>Australia</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Paul Lacaze; <email>paul.lacaze@monash.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>2</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <volume>8</volume>
              <issue>2</issue>
              <elocation-id>e001710</elocation-id>
              <history>
                <date date-type="received">
                  <day>03</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2021-07-31">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="openhrt-2021-001710.pdf"/>
              <abstract>
                <sec>
                  <title>Objective</title>
                  <p>Genetic variants that disrupt the function of the <italic toggle="yes">PCSK9</italic> (proprotein convertase subtilisin kexin type 9) and <italic toggle="yes">APOB</italic> (apolipoprotein B)genes result in lower serum low-density lipoprotein cholesterol (LDL-C) levels and subsequently confer protection against coronary heart disease (CHD). The objective of this study was to measure the prevalence and selective advantage of such variants among healthy older individuals without a history of CHD.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>We performed targeted sequencing of the <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> genes in 13 131 healthy individuals without CHD aged 70 years or older enrolled into the ASPirin in Reducing Events in the Elderly trial. We detected variants in the <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> genes with predicted loss-of-function. We associated variant carrier status with serum LDL-C and total cholesterol (TC) levels at the time of study enrolment, adjusting for statin use.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>We detected 22 different rare <italic toggle="yes">PCSK9/APOB</italic> candidate variants with putative lipid-lowering effect, carried by 104 participants (carrier rate 1 in 126). Serum LDL-C and TC concentrations for rare PCSK9/APOB variant carriers were consistently lower than non-carriers. Rare variant carrier status was associated with 19.4 mg/dL (14.6%) lower LDL-C, compared with non-carriers (p≤0.001, adjusted for statin use). Statin prescriptions were less prevalent in rare variant carriers (16%) than non-carriers (35%). The more common <italic toggle="yes">PCSK9</italic> R46L variant (rs11591147-T) was associated with 15.5 mg/dL (11.8%) lower LDL-C in heterozygotes, and 25.2 mg/dL (19.2%) lower LDL-C in homozygotes (both p≤0.001).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Lipid-lowering genetic variants are carried by healthy older individuals and contribute to CHD-free survival.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT01038583" ext-link-type="uri">NCT01038583</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>lipids</kwd>
                <kwd>coronary artery disease</kwd>
                <kwd>genetics</kwd>
                <kwd>hyperlipidemias</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id>
                      <institution>National Institute on Aging</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U01AG029824</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute at the National Institutes of Health</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1127060</award-id>
                  <award-id>334047</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart Foundation Future Leader Fellowship</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>102604</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>Key questions</title>
              </caption>
              <sec>
                <title>What is already known about this subject?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Loss-of-function genetic variants in the <italic toggle="yes">PCSK9</italic> (proprotein convertase subtilisin kexin type 9) and <italic toggle="yes">APOB</italic> (apolipoprotein B) genes result in lower serum low-density lipoprotein cholesterol concentrations and subsequently confer protection against coronary heart disease (CHD).</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>What does this study add?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Our study measured the prevalence and selective advantage of lipid-lowering genetic variants in a unique population of healthy older individuals aged ≥70 years without a history of CHD events.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>How might this impact on clinical practice?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>An improved understanding of the role played by protective lipid-lowering variants may help inform future approaches to CHD risk-reduction and lipid management.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Genetic variants that lower serum low-density lipoprotein cholesterol (LDL-C) levels have been demonstrated to be protective against coronary heart disease (CHD).<xref rid="R1" ref-type="bibr">1–9</xref> In particular, protection can be conferred by rare loss-of-function (LoF), protein-truncating variants in canonical lipid-metabolism genes, including the apolipoprotein B (<italic toggle="yes">APOB</italic>)<xref rid="R3" ref-type="bibr">3</xref> and the proprotein convertase subtilisin kexin type 9 (<italic toggle="yes">PCSK9</italic>)<xref rid="R3" ref-type="bibr">3 10</xref> genes. These protective lipid-lowering genetic variants tend to be rare in the general population. In addition, LDL-C particle size and other lipoprotein-related genotypes have been associated with CHD-free longevity.<xref rid="R11" ref-type="bibr">11</xref></p>
              <p>Familial hypobetalipoproteinaemia is caused by heterozygosity for <italic toggle="yes">APOB</italic> variants that generally result in LDL-C concentrations that are &gt;50% lower than normal, while <italic toggle="yes">PCSK9</italic> LoF variants are associated with more modest effects of 15%–40% lower LDL-C.<xref rid="R12" ref-type="bibr">12</xref> Discovery and understanding of rare protective variants in these genes, particularly <italic toggle="yes">PCSK9</italic>, has informed the successful development of several lipid-lowering therapies.<xref rid="R13" ref-type="bibr">13</xref> However, most cholesterol-lowering variants, to date, have been identified from case-control or population-based studies.<xref rid="R1" ref-type="bibr">1–9</xref> Populations of healthy older individuals without a history of CHD represent an understudied resource for the discovery and understanding of protective lipid-modifying genetic variants.</p>
              <p>With this rationale, we sequenced 13 131 healthy older individuals aged ≥70 years without a previous history of diagnosed CHD events, enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial.<xref rid="R14" ref-type="bibr">14</xref> Among this healthy older CHD-free population (average age 75 years), we hypothesised that the prevalence of rare cholesterol-lowering variants in canonical lipid metabolism genes (<italic toggle="yes">PCSK9</italic>/<italic toggle="yes">APOB</italic>) would be enriched, and that variant carrier status would be associated with lower serum LDL-C and total cholesterol (TC) levels—subsequently contributing to CHD-free survival.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2-1">
                <title>Study population</title>
                <p>Participants were enrolled in the ASPREE study, a randomised, placebo-controlled trial of daily low-dose aspirin investigating the effect of daily 100 mg aspirin on disability-free survival.<xref rid="R15" ref-type="bibr">15–17</xref> The ASPREE study design,<xref rid="R18" ref-type="bibr">18 19</xref> recruitment<xref rid="R20" ref-type="bibr">20</xref> and baseline characteristics<xref rid="R14" ref-type="bibr">14</xref> have been published previously. Participants had no previous diagnosis of atherosclerotic or atherothrombotic cardiovascular disease events, including myocardial infarction; heart failure; angina; pectoris; stroke or transient ischaemic attack or diagnosis of atrial fibrillation or high blood pressure.<xref rid="R21" ref-type="bibr">21</xref> Diagnosis of dementia or other serious illness likely to cause death within 5 years were also exclusion criteria. Genetic analysis was conducted on 13 131 samples provided by Australian ASPREE participants aged 70 years or older at enrolment.<xref rid="R22" ref-type="bibr">22</xref></p>
              </sec>
              <sec id="s2-2">
                <title>DNA sequencing and variant analysis</title>
                <p>A targeted sequencing panel was designed containing the <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> genes.<xref rid="R22" ref-type="bibr">22</xref> Following standard protocols, DNA was extracted and sequenced using the Thermo Fisher Scientific S5TM XL system to average 200× depth, with sequences aligned to the human genome reference 37. We identified candidate cholesterol-lowering variants from sequence data using two methods: (1) prediction of rare candidate LoF, protein-truncating <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> variants using the Loss-of-Function Transcript Effect Estimator tool, high-confidence filter, a plugin of Ensemble Variant Effect Predictor<xref rid="R23" ref-type="bibr">23</xref> and (2) assessment of candidate variants associated with hypercholesterolaemia or hypobetalipoproteinaemia identified from published functional and population studies<xref rid="R3" ref-type="bibr">3 10 24</xref> (for list of variants meeting the inclusion criteria, see <xref rid="SP1" ref-type="supplementary-material">online supplemental materials</xref>). We also examined the effect of the more common <italic toggle="yes">PCSK9</italic> R46L variant with known lipid-lowering effect (rs11591147-T).<xref rid="R25" ref-type="bibr">25</xref> Rare variants were curated manually by two or more laboratory scientists following the American College of Medical Genetics/Association for Molecular Pathology Standards<xref rid="R26" ref-type="bibr">26</xref> and variant classification was agnostic to lipid effects. A random selection of 10% of rare variants detected were validated using Sanger sequencing with 100% concordance. The minor allele frequency (MAF) of each variant detected in the ASPREE population was compared with the MAF reported in the genome Aggregation Database Non-Finnish European reference population (gnomAD-NFE).<xref rid="R23" ref-type="bibr">23</xref></p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/openhrt-2021-001710.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="openhrt-2021-001710supp001.xlsx" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s2-3">
                <title>Association of variant carrier status with blood lipid levels</title>
                <p>We sought to determine whether <italic toggle="yes">PCSK9/APOB</italic> variant carriers in the ASPREE cohort were associated with lower serum cholesterol levels at the time of enrolment, versus age-matched and gender-matched non-carriers. To do this, we compared serum LDL-C and TC levels between detected variant carriers versus n=9540 age-matched and gender-matched non-carrier ASPREE controls who did not carry any <italic toggle="yes">PCSK9</italic> or <italic toggle="yes">APOB</italic> variants that met our inclusion criteria. Baseline LDL-C and TC levels were measured in routine blood samples provided by ASPREE participants at enrolment, analysed at commercial pathology laboratories. We tested association of variant carrier status with serum LDL-C and TC levels using multivariable linear regression, adjusting for age, gender, diabetes, hypertension, smoking status, alcohol use and body mass index (BMI). We first tested association using raw unadjusted LDL-C and TC levels (not accounting for statin use), then separately using statin-adjusted levels, dividing LDL-C and TC levels by 0.7 and 0.8, respectively for those using statin medication to estimate untreated levels, as done previously.<xref rid="R3" ref-type="bibr">3</xref> We identified statin users based on concomitant medication data collected by ASPREE (Anatomical Therapeutic Chemical (ATC) code=C10, lipid-modifying agents).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <p>Characteristics of the 13 131 sequenced participants are shown in <xref rid="T1" ref-type="table">table 1</xref>. The median age at enrolment was 75 years, with 54% of participants female; 28% obese and 4% current smokers. Participants had no previous diagnosis of cardiovascular disease or dementia.<xref rid="R14" ref-type="bibr">14</xref> Most participants were of European ancestry (99% self-reported as white/Caucasian). The mean serum LDL-C and TC concentrations of the study population were 119 and 204 mg/dL, respectively at the time of enrolment.</p>
              <table-wrap position="float" id="T1">
                <label>Table 1</label>
                <caption>
                  <p>Characteristics of sequenced participants at enrolment</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">ASPREE<break/>N=13 131 (mean age 75 years)</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Female sex—no. (%)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">7056 (54)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age in years—no. (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 70–74</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">7894 (60)</td>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 75–79</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3406 (26)</td>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1"> ≥80</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1831 (14)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Race or ethnic group*—no. (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> White/Caucasian</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">12 953 (99)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Other</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">178 (1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Obese (BMI ≥30 kg/m<sup>2</sup>)† (%)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">28</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Current smoking (%)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">4</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Statin use‡ (%)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">33</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Heart, stroke or vascular disease§ (%)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Serum low-density lipoprotein cholesterol—mean, mg/dL</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">119</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Serum total cholesterol—mean, mg/dL</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">204</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T1_FN1">
                    <p>Sequenced individuals were Australian participants enrolled in the ASPREE clinical trial, aged 70 years and older (average age 75 years), without a previous diagnosis of cardiovascular disease events, dementia, permanent physical disability or current diagnosis of life-threatening cancer. Most were white/Caucasian and 54% were female.</p>
                  </fn>
                  <fn id="T1_FN2">
                    <p>*Self-report.</p>
                  </fn>
                  <fn id="T1_FN3">
                    <p>†Obese was defined as body mass index (weight (kg)/height (m<sup>2</sup>)) of ≥30.</p>
                  </fn>
                  <fn id="T1_FN4">
                    <p>‡Anatomical Therapeutic Chemical code C10 (lipid-modifying agents).</p>
                  </fn>
                  <fn id="T1_FN5">
                    <p>§Baseline characteristics of participants in the ASPREE study.<xref rid="R14" ref-type="bibr">14</xref></p>
                  </fn>
                  <fn id="T1_FN6">
                    <p>ASPREE, ASPirin in Reducing Events in the Elderly.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Among this population, we detected a total of 104 healthy older CHD-free individuals carrying rare candidate LoF variants that met our inclusion criteria (MAF &lt;0.01). Variants were found across multiple different domains of the <italic toggle="yes">APOB</italic> and <italic toggle="yes">PCSK9</italic> genes (schematic representation in <xref rid="F1" ref-type="fig">figure 1</xref>). Overall, the carrier rate of detected rare variants in PCSK9/APOB meeting our inclusion criteria (when considered as a group) was 1 in 126 participants or 0.8%.</p>
              <fig position="float" id="F1">
                <label>Figure 1</label>
                <caption>
                  <p>Schematic representation of the apolipoprotein B (<italic toggle="yes">APOB</italic>) and proprotein convertase subtilisin kexin type 9 (<italic toggle="yes">PCSK9</italic>) genes indicating the location of identified variants. We detected 22 different rare protein truncating or missense <italic toggle="yes">APOB</italic> and <italic toggle="yes">PCSK9</italic> variants with putative loss-of-function and lipid-lowering effect. We also investigated the more common <italic toggle="yes">PCSK9</italic> R46L variant (rs11591147). Variants were found across different protein domains of the <italic toggle="yes">APOB</italic> and <italic toggle="yes">PCSK9</italic> genes.</p>
                </caption>
                <graphic xlink:href="openhrt-2021-001710f01" position="float"/>
              </fig>
              <p>We detected a total of 22 different rare <italic toggle="yes">APOB/PCSK9</italic> variants, ranging in frequency between MAF=0.00335 (detected in 44 ASPREE participants) and MAF=0.00008 (singletons detected in only one ASPREE participant) (<xref rid="T2" ref-type="table">table 2</xref>). MAFs of the variants detected in the ASPREE population were found to be consistently higher when compared with MAFs from the gnomAD-NFE reference population (<xref rid="T2" ref-type="table">table 2</xref>). We found six putatively novel rare <italic toggle="yes">APOB</italic> variants that, at the time of our analysis, were not found in the gnomAD or dbSNP databases, and were not previously reported in the literature. Each of these rare <italic toggle="yes">APOB</italic> variants were detected as singletons in the ASPREE cohort (MAF=0.0008) and met our criteria for LoF (<xref rid="T2" ref-type="table">table 2</xref>).</p>
              <table-wrap position="float" id="T2">
                <label>Table 2</label>
                <caption>
                  <p>Prevalence of LDL-C-lowering variants in a population of 13,131 healthy older CHD-free individuals (ASPREE)</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">Gene</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">Variant (GRCh37)</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">rsID</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">Type</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">Consequence</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">ASPREE carriers</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">ASPREE MAF<break/>N=13 131</td>
                      <td align="left" valign="bottom" rowspan="4" colspan="1">gnomAD-NFE MAF<break/>N=64 603</td>
                      <td align="left" valign="bottom" colspan="2" rowspan="1">ASPREE blood lipid levels (mg/dL)*</td>
                    </tr>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">LDL-C</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">TC</td>
                    </tr>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="2">Non-carriers (mean n=9450)</td>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="bottom" rowspan="1" colspan="1">119.9</td>
                      <td align="char" char="." valign="bottom" rowspan="1" colspan="1">201.1</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="2">
                        <bold>Rare variants (MAF &lt;0.01)</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.709C&gt;T (p.Arg237Trp)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs148195424</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">44</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00335</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00093</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">107.3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">194.5</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.1327G&gt;A(p.Ala443Thr)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs28362263</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">13</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00099</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00029</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">117.5</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">198.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.657+1G&gt;T</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs142824171</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Splice donor</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">7</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00053</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00007</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">116.6</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">202.2</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.1384T&gt;C (p.Ser462Pro)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs746115963</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">7</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00053</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00012</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">124.3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">214.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.520C&gt;T (p.Pro174Ser)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs533273863</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">5</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00038</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">127.6</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">222.0</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.1863+1G&gt;A</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs765335983</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Splice donor</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">5</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00038</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00003</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">98.6</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">182.7</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.277C&gt;T (p.Arg93Cys)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs151193009</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00023</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00002</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">128.9</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">212.7</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.341T&gt;C (p.Val114Ala)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs775988212</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">2</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00015</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00003</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">139.2</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">212.7</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.471C&gt;A (p.Asn157Lys)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs143117125</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">2</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00015</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00005</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">121.8</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">203.1</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.1300C&gt;T(p.Arg434Trp)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs757143429</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">2</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00015</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00001</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">98.60</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">164.3</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.313C&gt;T (p.Arg105Trp)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs747072726</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00002</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">116.0</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">247.0</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.706G&gt;A (p.Gly236Ser)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs149489325</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00005</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">65.7</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">139.2</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.658-2A&gt;C</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs371336612</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Splice acceptor</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">77.3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">146.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="6">
                        <bold>Total 92</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.3(APOB):<break/>c.6253C&gt;T(p.Arg2085Ter)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs121918386</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stop gained</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00023</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00004</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">95.37</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">170.2</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.3(APOB):<break/>c.4503T&gt;G (p.Tyr1501Ter)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs368825685</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stop gained</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00001</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">77.3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">177.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.3(APOB):<break/>c.1315C&gt;T (p.Arg439Ter)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs142066904</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stop gained</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00003</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">61.9</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">123.7</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.2(APOB):<break/>c.11153C&gt;G (Ser3718Ter)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stop gained</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">61.9</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">146.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.2(APOB):<break/>c.7300C&gt;T (p.Gln2434Ter)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stop gained</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">42.5</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">174</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.3(APOB):<break/>c.6538C&gt;T (p.Gln2180Ter)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs1041962</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stop gained</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">61.9</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">162.4</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.2(APOB):<break/>c.2245-2A&gt;G</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Splice acceptor</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">98.6</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">164.3</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.2(APOB)<break/>21228615CA&gt;C (deletion)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">INDEL</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Frameshift</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">77.3</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">146.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">APOB</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_000384.2(APOB)<break/>21 230 841G&gt;GT (insertion)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">INDEL</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Frameshift</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00008†</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">73.5</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">177.9</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="6">
                        <bold>Total 11</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="2">
                        <bold>PCSK9 R46L (MAF &gt;0.01)</bold>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK9</italic>
                      </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NM_174936.3(PCSK9):<break/>c.137G&gt;T (p.Arg46Leu)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">rs11591147</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">SNV</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">HET</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">465</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.03541</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.01507</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">110.6</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">196.4</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      <td align="left" valign="top" rowspan="1" colspan="1">HOMO</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">6</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00046</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.0002</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">105.0</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">190.1</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T2_FN1">
                    <p>We sequenced n=13 131 individuals aged 70 years and older to detect cholesterol-lowering variants using two methods: (1) prediction of rare candidate loss-of-function, protein-truncating <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> variants and (2) assessment of candidate variants identified in previously published functional or population studies. We also examined the effect of the common <italic toggle="yes">PCSK9</italic> R46L variant with lipid-lowering effect; rs11591147<xref rid="R25" ref-type="bibr">25</xref> Variants were curated following ACMG/AMP Standards<xref rid="R26" ref-type="bibr">26</xref></p>
                  </fn>
                  <fn id="T2_FN2">
                    <p>*For variants found in more than one participant, the mean LDL-C and TC levels for all carriers of that variant are shown.</p>
                  </fn>
                  <fn id="T2_FN3">
                    <p>†Denotes a singleton variant detected in only one ASPREE participant/carrier (MAF=1 carrier/13 131 participants=0.0008).</p>
                  </fn>
                  <fn id="T2_FN4">
                    <p>ACMG/AMP, American College of Medical Genetics/Association for Molecular Pathology; ASPREE, ASPirin in Reducing Events in the Elderly; CHD, coronary heart disease; HET, heterozygote; HOMO, homozygote; INDEL, insertion/deletion; LDL-C, low-density lipoprotein cholesterol; MAF, minor allele frequency; SNV, single nucleotide variant; TC, total cholesterol.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The serum LDL-C and TC concentrations for carriers of rare <italic toggle="yes">APOB</italic> or <italic toggle="yes">PCSK9</italic> variants were found to be consistently lower than the n=9450 non-carrier controls in the study (<xref rid="F2" ref-type="fig">figure 2</xref>, <xref rid="T2" ref-type="table">table 2</xref>). For some rare variants, the reduction in LDL-C was up to 77.4 mg/dL (eg, <italic toggle="yes">APOB</italic> c.7300C&gt;T (p.Gln2434Ter)). Based on raw LDL-C and TC levels uncorrected for statin use, rare variant heterozygous carrier status in ASPREE (when considered as a group of n=104 participants) was associated with 11.6 mg/dL (9.7%) lower serum LDL-C (p&lt;0.001) and 7.8 mg/dL (3.9%) lower serum TC (p&lt;0.001) versus non-carriers, adjusted for age, gender, diabetes, hypertension, smoking status, alcohol use and BMI (<xref rid="F3" ref-type="fig">figure 3</xref>, <xref rid="T3" ref-type="table">table 3</xref>).</p>
              <fig position="float" id="F2">
                <label>Figure 2</label>
                <caption>
                  <p>Relative changes in serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels per variant detected, in variant carriers versus non-carriers. Shown are waterfall plots of the relative changes in serum LDL-C (A) and TC (B) concentrations at enrolment (mg/dL) for carriers of proprotein convertase subtilisin kexin type 9 <italic toggle="yes">(PCSK9)</italic> and apolipoprotein B <italic toggle="yes">(APOB)</italic> variants, compared with the mean concentration from n=9450 non-carrier controls (normalised to 0 mg/dL). Variant name labels are shown vertically above the plots, and include the total number (N) of carriers detected per variant. For variants detected in more than one participant, the mean LDL-C and TC levels for all carriers of that variant are plotted.</p>
                </caption>
                <graphic xlink:href="openhrt-2021-001710f02" position="float"/>
              </fig>
              <fig position="float" id="F3">
                <label>Figure 3</label>
                <caption>
                  <p>Proprotein convertase subtilisin kexin type 9 <italic toggle="yes">(PCSK9)</italic> and apolipoprotein B <italic toggle="yes">(APOB)</italic> rare variant carrier status in ASPirin in Reducing Events in the Elderly (ASPREE) is associated with reduced serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels. Shown is a comparison of serum LDL-C (A) and TC (B) levels at enrolment for carriers of rare variants (minor allele frequency (MAF) &lt;0.01) in <italic toggle="yes">PCSK9</italic> (n=93) and <italic toggle="yes">APOB</italic> (n=11), compared with non-carrier controls (n=9540) from the ASPREE study. Results indicate that rare <italic toggle="yes">APOB/PCSK9</italic> rare variant carrier status is associated with reduced serum LDL-C and TC levels versus non-carriers. Linear regression was used to compare statistical differences between groups adjusting for covariates. Median values are shown as coloured solid lines (magenta). Statistical significance is denoted as ***p≤0.001. Dyslipidaemia (dotted lines) is defined as serum LDL-C &gt;160 mg/dL, or serum TC &gt;212 mg/dL.<xref rid="R14" ref-type="bibr">14</xref> To convert values from mg/dL to mmol/L multiply by 0.02586.</p>
                </caption>
                <graphic xlink:href="openhrt-2021-001710f03" position="float"/>
              </fig>
              <table-wrap position="float" id="T3">
                <label>Table 3</label>
                <caption>
                  <p>Variant carrier status is associated with reduced serum LDL-C and TC levels</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Rare variant group<break/><italic toggle="yes">PCSK9/APOB</italic><break/>MAF &lt;0.01</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Non-carriers<break/>N=9540</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Heterozygotes<break/>N=104</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Homozygotes<break/>N=0</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">P value</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">LDL-C (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">119.9<break/>(96.7–143.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">108.3<break/>(81.2–131.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">adj</italic>LDL-C (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">131.5<break/>(112.1–150.8)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">112.1<break/>(92.8–139.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">TC (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">201.1<break/>(177.9–228.2)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">193.3<break/>(170.1–220.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">adj</italic>TC (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">217.5<break/>(193.4–241.6)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">201.1<break/>(177.9–225.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Common variant<break/><italic toggle="yes">PCSK9</italic> rs11591147-T</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Non-carriers<break/>N=9540</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Heterozygotes<break/>N=465</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Homozygotes<break/>N=6</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">P value</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">LDL-C (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">119.9<break/>(96.7–143.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">112.1<break/>(88.9–131.5)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">106.35<break/>(95.7–117.0)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">adj</italic>LDL-C (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">131.5<break/>(112.1–150.8)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">116.0<break/>(96.7–135.3)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">106.4<break/>(95.7–117.0)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">TC (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">201.1<break/>(177.9–228.2)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">197.2<break/>(170.1–216.6)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">197.2<break/>(168.2–211.7)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">adj</italic>TC (mg/dL)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">217.5<break/>(193.4–241.6)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">201.1<break/>(183.6–227.1)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">197.2<break/>(168.2–211.7)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T3_FN1">
                    <p>We compared serum LDL-C and TC levels between variant carriers and n=9540 non-carrier controls from the ASPREE study. The multivariable linear regression model adjusted for age, gender, diabetes, hypertension, smoking status, alcohol use and body mass index. We first tested association using raw unadjusted LDL-C and TC levels (not accounting for statin use), then separately using statin-adjusted levels (<italic toggle="yes">adj</italic>LDL-C, <italic toggle="yes">adj</italic>TC), dividing LDL-C and TC levels by 0.7 and 0.8, respectively for those using statin medication to estimate untreated levels, as done previously.<xref rid="R3" ref-type="bibr">3</xref> We identified statin users based on concomitant medications recorded by ASPREE at baseline. Data are presented as median (IQR). Statistical significance is denoted by p&lt;0.001. To convert values from mg/dL to mmol/L multiply by 0.02586. ATC code C10 (lipid-modifying agents).</p>
                  </fn>
                  <fn id="T3_FN2">
                    <p>ASPREE, ASPirin in Reducing Events in the Elderly; ATC, Anatomical Therapeutic Chemical; LDL-C, low-density lipoprotein cholesterol; MAF, minor allele frequency; TC, total cholesterol.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>After adjusting for statin use (dividing LDL-C and TC levels by 0.7 and 0.8, respectively for those taking statin medication), rare variant heterozygous carrier status was associated with 19.4 mg/dL (14.6%) lower adjusted serum LDL-C (p&lt;0.001) and 16.4 mg/dL (7.5%) lower adjusted serum TC (p&lt;0.001) versus non-carriers. The prevalence of lipid-lowering statin prescriptions among rare variant carriers was 16% (n=17/104), which was lower than that observed in non-carriers (35%, n=3324/9540).</p>
              <p>The estimated median untreated LDL-C level in non-carriers was 131.5 mg/dL (110.4–154.7), compared with 112.1 mg/dL (92.8–139.2) in rare <italic toggle="yes">PCSK9/APOB</italic> variant carriers. At the per-gene level, rare variant carrier status for <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> variants separately was also associated with significantly lower LDL-C levels for both genes (p&lt;0.001).</p>
              <p>For the more common <italic toggle="yes">PCSK9</italic> R46L variant (rs11591147-T, ASPREE MAF=0.03541), heterozygous and homozygous carrier status were associated with 15.5 mg/dL (11.8%) lower and 25.2 mg/dL (19.2%) lower statin-corrected LDL-C levels, respectively (p≤0.001) (<xref rid="T3" ref-type="table">table 3</xref>).</p>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>In this study, we identified rare <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> variants that are associated with lower serum LDL-C levels among a population of healthy older individuals without a history of CHD events. Most of the variants detected were enriched in frequency among the healthy older CHD-free ASPREE population, compared with a large reference population of similar genetic ancestry (gnomAD-NFE). Serum LDL-C and TC concentrations for rare variant carriers were consistently lower than non-carriers in the study, and rare variant carrier status was associated with 19.4 mg/dL (14.6%) lower serum LDL-C and TC concentrations, after adjusting for statin use. The prevalence of statin prescriptions in variant carriers were less than half that observed in non-carriers. Together, these results indicate that lipid-lowering genetic variants are enriched in healthy older individuals without CHD, and play a role in coronary disease-free survival throughout the human lifespan.</p>
              <p>Consistent with other studies,<xref rid="R1" ref-type="bibr">1–9</xref> we observed that LoF variants in the <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> gene are associated with lower serum LDL-C concentrations. However, to our knowledge, the prevalence shown in ASPREE during ageing free of atherosclerotic cardiovascular disease manifestations has not previously been demonstrated. Variants analysed were found to lower serum LDL-C and TC levels among the ASPREE population, with the difference in LDL-C concentrations between ASPREE rare variant carrier and non-carriers being ~20 mg/dL after adjusting for statin use. At an average participant age of 75 years, this represents the effect of potentially a lifetime of exposure to genetically determined lower LDL-C.</p>
              <p>Meta-analysis of statin trials suggests for a 38 mg/dL reduction in LDL-C, there is a 20%–22% reduction in CHD risk, in the setting of relatively short clinical trials.<xref rid="R27" ref-type="bibr">27</xref> Mendelian randomisation studies, however, demonstrate the importance of lifetime exposure to low LDL-C, suggesting that genetically determined low LDL-C is associated with a greater magnitude of CHD risk-reduction, compared with equivalent reduction through statin use.<xref rid="R28" ref-type="bibr">28</xref> It is therefore likely that ASPREE rare variant carriers detected in this study, who have experienced a lifetime of exposure to genetically lower LDL-C, have benefited substantially from lower CHD risk. However, it is noteworthy that the rare variants detected likely account for only a fraction of the reduced CHD risk in the ASPREE population (n=13 131), with a range of other genetic and lifestyle factors contributing.</p>
              <p>Strengths of the study include the sample size and unique ascertainment of the ASPREE population. The sequenced cohort comprised 13 131 individuals with an average age of 75 years, with no previous diagnosis of CHD or other cardiovascular events. It is rare for a population ascertained with these characteristics to be made available for genetic analysis. The sequenced cohort was the result of a unique set of circumstances made possible by the strict ASPREE inclusion criteria and age cut-off, and associated research biobank.<xref rid="R14" ref-type="bibr">14 29</xref></p>
              <p>Another strength of the study is that ASPREE participants were well characterised, each receiving a medical assessment by a general practitioner at enrolment, to confirm eligibility for the trial, and to rule out previous diagnoses of CHD.<xref rid="R14" ref-type="bibr">14</xref> This provided confidence that detected variant carriers were CHD event-free at enrolment. Other strengths of the study include the depth of sequencing, focus on canonical lipid metabolism genes with established biological effect and stringency of variant curation used, to ensure only high-confidence variants were included in analyses.</p>
              <p>Limitations of the study include our results not necessarily being generalisable to populations of non-European ancestry. Furthermore, we caution the comparison of rare variant prevalence between ASPREE and reference populations such as gnomAD, due to the potential for technical artefacts introduced by differences in sequencing technologies and variant curation, and population stratification related to differences in genetic ancestry. These well-known sources of variability are compounded when attempting to compare rare variant frequencies between studies.<xref rid="R30" ref-type="bibr">30</xref> Nonetheless, our results suggest that rare <italic toggle="yes">PSCK9/APOB</italic> variants are enriched in healthy older CHD-free individuals (<xref rid="T2" ref-type="table">table 2</xref>), consistent with previous studies showing that LDL-C-lowering variants are associated with reduced risk for CHD and longevity.<xref rid="R1" ref-type="bibr">1–9</xref></p>
              <p>Regarding the genes analysed in our study, we focused on only the most established two canonical lipid metabolism genes where rare LoF variants have been demonstrated to have a high effect in reducing LDL-C levels (<italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic>).<xref rid="R1" ref-type="bibr">1 3 8 9</xref> We did not examine gain-of-function variants in the <italic toggle="yes">LDLR</italic> gene, or LoF variants in other genes that have been associated with LDL-C reduction (eg, <italic toggle="yes">NPC1L1</italic>, <italic toggle="yes">LPA</italic>, <italic toggle="yes">APOC3</italic>, <italic toggle="yes">ANGPTL3/4</italic> and <italic toggle="yes">ASGR1</italic>) as these genes were not included on the sequencing panel used. We also could not calculate polygenic scores due to the targeted nature of the sequencing assay, and could not assess subclinical atherosclerosis due to absence of data on coronary artery calcium and carotid intima-media thickness. We did not functionally validate the detected rare variants.</p>
              <p>Our study demonstrates the unique contribution of healthy older populations to exploring genetic determinants of health and lifespan. Historically, healthy older populations have not been the focus of large human genetic studies, mainly due to the difficulties in ascertaining large numbers of samples in this age group. However, studies focused on well-characterised populations of healthy older individuals represent an underexplored opportunity for the detection and improved understanding of protective genetic variants, especially in the context of lipid regulation and CHD.<xref rid="R29" ref-type="bibr">29</xref> An improved understanding of the role played by protective lipid-lowering variants may help inform novel future approaches to CHD risk-reduction and lipid management.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank the ASPREE trial staff in Australia and the USA, the ASPREE participants who volunteered for the trial and the general practitioners and staff of the medical clinics who cared for the participants.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> PL, MR, RS, AJH, JP, GP, ES and JJMcN made substantial contributions to conception and design, acquisition of data or analysis and interpretation of data. PL, MR, AJH, JT, AT, CR, SZ, AMM, SN, GW and JJMcN were involved in drafting the manuscript or revising it critically for important intellectual content. All authors gave final approval of the version to be published. PL and JJMcN agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> The ASPREE Healthy Ageing Biobank is supported by a Flagship cluster grant (including the Commonwealth Scientific and Industrial Research Organisation, Monash University, Menzies Research Institute, Australian National University, University of Melbourne); and grants (U01AG029824) from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the National Health and Medical Research Council of Australia, and by Monash University and the Victorian Cancer Agency. PL is supported by a National Heart Foundation Future Leader Fellowship (102604).</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> GW has received honoraria and/or research grants from Arrowhead, AstraZeneca, Kowa, Regeneron, Sanofi, Amgen and Novartis. SN has received research support and/or honoraria for Amgen, AstraZeneca, Eli Lilly, Esperion, Novartis, Merck, Pfizer, Iowa and Sanofi-Regeneron. RS serves as Vice-President of Technology Development at Sema4. ES serves as Chief Executive Officer at Sema4. No other conflicts were reported.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data are available from the corresponding author on request.</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec sec-type="ethics-consent-to-publish">
                <title>Patient consent for publication</title>
                <p>Not required.</p>
              </sec>
              <sec sec-type="ethics-approval">
                <title>Ethics approval</title>
                <p>The study received approvals from the Alfred Hospital Research Ethics Committee (Project 390/15). All participants provided written informed consent for genetic research.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>JC</given-names></string-name>, <string-name><surname>Boerwinkle</surname><given-names>E</given-names></string-name>, <string-name><surname>Mosley</surname><given-names>TH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sequence variations in PCSK9, low LDL, and protection against coronary heart disease</article-title>. <source>N Engl J Med</source><year>2006</year>;<volume>354</volume>:<fpage>1264</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa054013</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16554528?><pub-id pub-id-type="pmid">16554528</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dewey</surname><given-names>FE</given-names></string-name>, <string-name><surname>Gusarova</surname><given-names>V</given-names></string-name>, <string-name><surname>O’Dushlaine</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Inactivating variants in ANGPTL4 and risk of coronary artery disease</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>1123</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1510926</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26933753?><pub-id pub-id-type="pmid">26933753</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peloso</surname><given-names>GM</given-names></string-name>, <string-name><surname>Nomura</surname><given-names>A</given-names></string-name>, <string-name><surname>Khera</surname><given-names>AV</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rare protein-truncating variants in ApoB, lower low-density lipoprotein cholesterol, and protection against coronary heart disease</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<elocation-id>e002376</elocation-id>. <pub-id pub-id-type="doi">10.1161/CIRCGEN.118.002376</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30939045?><pub-id pub-id-type="pmid">30939045</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ference</surname><given-names>BA</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>JG</given-names></string-name>, <string-name><surname>Brook</surname><given-names>RD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>375</volume>:<fpage>2144</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1604304</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27959767?><pub-id pub-id-type="pmid">27959767</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nomura</surname><given-names>A</given-names></string-name>, <string-name><surname>Won</surname><given-names>H-H</given-names></string-name>, <string-name><surname>Khera</surname><given-names>AV</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease</article-title>. <source>Circ Res</source><year>2017</year>;<volume>121</volume>:<fpage>81</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311145</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28506971?><pub-id pub-id-type="pmid">28506971</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ference</surname><given-names>BA</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Ray</surname><given-names>KK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease</article-title>. <source>JAMA</source><year>2019</year>;<volume>321</volume>:<fpage>364</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2018.20045</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30694319?><pub-id pub-id-type="pmid">30694319</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671 polymorphism and coronary heart disease</article-title>. <source>Biomed Res Int</source><year>2014</year>;<volume>2014</volume>:<elocation-id>564940</elocation-id><pub-id pub-id-type="doi">10.1155/2014/564940</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24900971?><pub-id pub-id-type="pmid">24900971</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burnett</surname><given-names>JR</given-names></string-name>, <string-name><surname>Hooper</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Common and rare gene variants affecting plasma LDL cholesterol</article-title>. <source>Clin Biochem Rev</source><year>2008</year>;<volume>29</volume>:<fpage>11</fpage>–<lpage>26</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18566665?><pub-id pub-id-type="pmid">18566665</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rimbert</surname><given-names>A</given-names></string-name>, <string-name><surname>Pichelin</surname><given-names>M</given-names></string-name>, <string-name><surname>Lecointe</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Identification of novel ApoB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia</article-title>. <source>Atherosclerosis</source><year>2016</year>;<volume>250</volume>:<fpage>52</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.04.010</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27179706?><pub-id pub-id-type="pmid">27179706</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dron</surname><given-names>JS</given-names></string-name>, <string-name><surname>Hegele</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants</article-title>. <source>Curr Opin Lipidol</source><year>2017</year>;<volume>28</volume>:<fpage>161</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/MOL.0000000000000386</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28157721?><pub-id pub-id-type="pmid">28157721</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barzilai</surname><given-names>N</given-names></string-name>, <string-name><surname>Atzmon</surname><given-names>G</given-names></string-name>, <string-name><surname>Schechter</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Unique lipoprotein phenotype and genotype associated with exceptional longevity</article-title>. <source>JAMA</source><year>2003</year>;<volume>290</volume>:<fpage>2030</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1001/jama.290.15.2030</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/14559957?><pub-id pub-id-type="pmid">14559957</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Welty</surname><given-names>FK</given-names></string-name></person-group>. <article-title>Hypobetalipoproteinemia and abetalipoproteinemia</article-title>. <source>Curr Opin Lipidol</source><year>2014</year>;<volume>25</volume>:<fpage>161</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/MOL.0000000000000072</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24751931?><pub-id pub-id-type="pmid">24751931</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Graham</surname><given-names>I</given-names></string-name>, <string-name><surname>Shear</surname><given-names>C</given-names></string-name>, <string-name><surname>De Graeff</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk</article-title>. <source>Eur Heart J Cardiovasc Pharmacother</source><year>2018</year>;<volume>4</volume>:<fpage>119</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1093/ehjcvp/pvx031</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/29194462?><pub-id pub-id-type="pmid">29194462</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McNeil</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Woods</surname><given-names>RL</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>MR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Baseline characteristics of participants in the ASPREE (aspirin in reducing events in the elderly) study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source><year>2017</year>;<volume>72</volume>:<fpage>1586</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/glw342</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28329340?><pub-id pub-id-type="pmid">28329340</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McNeil</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Wolfe</surname><given-names>R</given-names></string-name>, <string-name><surname>Woods</surname><given-names>RL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of aspirin on cardiovascular events and bleeding in the healthy elderly</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>1509</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1805819</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30221597?><pub-id pub-id-type="pmid">30221597</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McNeil</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Woods</surname><given-names>RL</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>MR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of aspirin on disability-free survival in the healthy elderly</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>1499</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1800722</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30221596?><pub-id pub-id-type="pmid">30221596</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McNeil</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>MR</given-names></string-name>, <string-name><surname>Woods</surname><given-names>RL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of aspirin on all-cause mortality in the healthy elderly</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>1519</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1803955</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30221595?><pub-id pub-id-type="pmid">30221595</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>ASPREE Investigator Group</collab></person-group>. <article-title>Study design of aspirin in reducing events in the elderly (ASPREE): a randomized, controlled trial</article-title>. <source>Contemp Clin Trials</source><year>2013</year>;<volume>36</volume>:<fpage>555</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2013.09.014</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24113028?><pub-id pub-id-type="pmid">24113028</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nelson</surname><given-names>MR</given-names></string-name>, <string-name><surname>Reid</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ames</surname><given-names>DA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the aspirin in reducing events in the elderly (ASPREE) pilot study</article-title>. <source>Med J Aust</source><year>2008</year>;<volume>189</volume>:<fpage>105</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5694/j.1326-5377.2008.tb01932.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18637782?><pub-id pub-id-type="pmid">18637782</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lockery</surname><given-names>JE</given-names></string-name>, <string-name><surname>Collyer</surname><given-names>TA</given-names></string-name>, <string-name><surname>Abhayaratna</surname><given-names>WP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Recruiting general practice patients for large clinical trials: lessons from the aspirin in reducing events in the elderly (ASPREE) study</article-title>. <source>Med J Aust</source><year>2019</year>;<volume>210</volume>:<fpage>168</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.5694/mja2.12060</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30835844?><pub-id pub-id-type="pmid">30835844</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lacaze</surname><given-names>P</given-names></string-name>, <string-name><surname>Sebra</surname><given-names>R</given-names></string-name>, <string-name><surname>Riaz</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Familial hypercholesterolemia in a healthy elderly population</article-title>. <source>Circ Genom Precis Med</source><year>2020</year>;<volume>13</volume>:<elocation-id>e002938</elocation-id>. <pub-id pub-id-type="doi">10.1161/CIRCGEN.120.002938</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32522009?><pub-id pub-id-type="pmid">32522009</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lacaze</surname><given-names>P</given-names></string-name>, <string-name><surname>Sebra</surname><given-names>R</given-names></string-name>, <string-name><surname>Riaz</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals</article-title>. <source>Genet Med</source><year>2020</year>;<volume>22</volume>:<fpage>1883</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/s41436-020-0881-7</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32606442?><pub-id pub-id-type="pmid">32606442</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lek</surname><given-names>M</given-names></string-name>, <string-name><surname>Karczewski</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Minikel</surname><given-names>EV</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source>Nature</source><year>2016</year>;<volume>536</volume>:<fpage>285</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/nature19057</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27535533?><pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elbitar</surname><given-names>S</given-names></string-name>, <string-name><surname>Susan-Resiga</surname><given-names>D</given-names></string-name>, <string-name><surname>Ghaleb</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>New sequencing technologies help revealing unexpected mutations in autosomal dominant hypercholesterolemia</article-title>. <source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<elocation-id>1943</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41598-018-20281-9</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/29386597?><pub-id pub-id-type="pmid">29386597</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benn</surname><given-names>M</given-names></string-name>, <string-name><surname>Nordestgaard</surname><given-names>BG</given-names></string-name>, <string-name><surname>Grande</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pcsk9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses</article-title>. <source>J Am Coll Cardiol</source><year>2010</year>;<volume>55</volume>:<fpage>2833</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2010.02.044</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20579540?><pub-id pub-id-type="pmid">20579540</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>S</given-names></string-name>, <string-name><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name><surname>Bale</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source><year>2015</year>;<volume>17</volume>:<fpage>405</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/25741868?><pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cholesterol Treatment Trialists’ (CTT) Collaborators</collab>, <string-name><surname>Mihaylova</surname><given-names>B</given-names></string-name>, <string-name><surname>Emberson</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials</article-title>. <source>Lancet</source><year>2012</year>;<volume>380</volume>:<fpage>581</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60367-5</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22607822?><pub-id pub-id-type="pmid">22607822</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ference</surname><given-names>BA</given-names></string-name>, <string-name><surname>Yoo</surname><given-names>W</given-names></string-name>, <string-name><surname>Alesh</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis</article-title>. <source>J Am Coll Cardiol</source><year>2012</year>;<volume>60</volume>:<fpage>2631</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2012.09.017</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23083789?><pub-id pub-id-type="pmid">23083789</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lacaze</surname><given-names>P</given-names></string-name>, <string-name><surname>Woods</surname><given-names>R</given-names></string-name>, <string-name><surname>Zoungas</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The genomic potential of the aspirin in reducing events in the elderly and statins in reducing events in the elderly studies</article-title>. <source>Intern Med J</source><year>2017</year>;<volume>47</volume>:<fpage>461</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1111/imj.13384</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28401726?><pub-id pub-id-type="pmid">28401726</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name><surname>Abecasis</surname><given-names>GR</given-names></string-name>, <string-name><surname>Boehnke</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rare-variant association analysis: study designs and statistical tests</article-title>. <source>Am J Hum Genet</source><year>2014</year>;<volume>95</volume>:<fpage>5</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2014.06.009</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24995866?><pub-id pub-id-type="pmid">24995866</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
